Progression to insulin therapy in clinically diagnosed type 2 diabetes is highly variable. GAD65 autoantibodies (GADA) are associated with faster progression, but their predictive value is limited. We aimed to determine if a type 1 diabetes genetic risk score (T1D GRS) could predict rapid progression to insulin treatment over and above GADA testing.
progress may have clinical utility in prioritization monitoring and treatment escalation and in choice of therapy.
It has previously been shown that many patients with clinical features of type 2 diabetes have positive GAD65 autoantibodies (GADA) and that the presence of this autoantibody is associated with faster progression to insulin (3, 4) . This is often termed latent autoimmune diabetes in adults (LADA) (5, 6) . However, the predictive value of GADA testing is limited in a population with clinical type 2 diabetes, with many GADApositive patients not requiring insulin treatment for many years (4, 7) . Previous research has suggested that genetic variants in the HLA region associated with type 1 diabetes are associated with more rapid progression to insulin in patients with clinically defined type 2 diabetes and positive GADA (8) .
We have recently developed a type 1 diabetes genetic risk score (T1D GRS), which provides an inexpensive ($70 in our local clinical laboratory and ,$20 where DNA has been previously extracted), integrated assessment of a person's genetic susceptibility to type 1 diabetes (9) . The score is composed of 30 type 1 diabetes risk variants weighted for effect size and aids discrimination of type 1 diabetes from type 2 diabetes. The T1D GRS has advantages over HLA typing alone, as it includes more genetic information, is cheaper than conventional HLA typing, and represents a continuous scale of likelihood of type 1 diabetes susceptibility. In young-onset adults (diagnosed between 20 and 40 years of age), it can predict insulin dependence and is independent of and additive to islet autoantibodies and clinical features (9) . It is not known if the T1D GRS will improve the prediction of insulin requirement by GADA in clinically defined type 2 diabetes.
We aimed to determine if the T1D GRS could predict rapid progression to insulin (within 5 years of diagnosis) over and above GADA testing in patients with a clinical diagnosis of type 2 diabetes treated without insulin at diagnosis.
RESEARCH DESIGN AND METHODS
We examined the relationship between GADA, T1D GRS, and progression to insulin therapy using survival analysis in 8,608 participants with clinical type 2 diabetes initially treated without insulin therapy.
Study Population
Included participants had a clinical diagnosis of type 2 diabetes after 35 years of age, were treated without insulin for the first 6 months from diagnosis, and were of white European origin. The study complies with the Declaration of Helsinki.
Participants were identified in the following cohorts: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) (10), Hoorn Diabetes Care System (DCS) (11) , Diabetes Alliance for Research in England (DARE) (12) , Predicting Response to Incretin Based Agents in Type 2 Diabetes (PRIBA) (13) , and MRC MASTERMIND Progressors (14) . These cohorts were studies of participants with a clinical diagnosis of type 2 diabetes recruited from primary and secondary care and are population based, with the exception of PRIBA and MRC MASTERMIND Progressors, which account for ,10% of participants. Summaries of the cohort recruitment and data collection methods are shown in Supplementary Table 1 , and a flow diagram of sample selection is shown in Supplementary Fig. 1 .
Participants known to have had GADA testing either performed in clinical practice or prior to diagnosis (through review of electronic laboratory records) were excluded due to the risk of the result influencing the clinician's treatment decision.
In the GoDARTS cohort, participants diagnosed with diabetes before 1 January 1994 were excluded; due to insufficient prescribing information, we were unable to define time to insulin prior to this date. In the DARE cohort, only the participants recruited in the Exeter center with saved serum were included.
Assessment of Diabetes Progression (Time to Insulin)
For GoDARTS and DCS cohorts, time to insulin was defined from electronic prescription records. For Exeter cohorts (DARE, PRIBA, and MRC MASTERMIND Progressors), insulin treatment, date of commencing insulin, and date of diagnosis were self-reported at a single visit.
Laboratory Measurement
The Academic Department of Blood Sciences at the Royal Devon and Exeter Hospital measured GADA for all five cohorts at a median diabetes duration of 6.1 years, using the same assay from biobanked samples stored at 280°C.
GADA was performed using the RSR Limited ELISA (RSR Limited, Cardiff, U.K.) on the Dynex DS2 ELISA Robot (Dynex Technologics, Worthing, U.K.). The cutoff for positivity was $11 units/mL, based on the 97.5th centile of 1,559 control participants without diabetes (15) . The lowest reportable value (lowest calibrant) was 5.0 units/mL. The laboratory participates in the International Autoantibody Standardization Program.
The HbA 1c value at latest follow-up (closest available result, median 10.6 years diabetes duration) was obtained from electronic health care records or measured on a research sample by the Academic Department of Blood Sciences at the Royal Devon and Exeter Hospital.
Assessment of T1D GRS
The development of the T1D GRS has been described previously (9) . In brief, T1D GRS consists of 30 common type 1 diabetes genetic variants (single nucleotide polymorphisms [SNPs]) from HLA and non-HLA loci; each variant is weighted by their effect size on type 1 diabetes risk from previously published literature, with weights for DR3/DR4-DQ8 assigned based on imputed haplotypes. The combined score represents an individual's genetic susceptibility to type 1 diabetes. Variants used to derive the score are shown in Supplementary Table 2 . For ease of clinical interpretation, the score is presented in this article as the centile position of the distribution in the Wellcome Trust Case Control Consortium population with type 1 diabetes (16) .
In the Exeter cohorts, genotyping was performed using the KASP genotyping assay by LGC Genomics (Hoddesdon, U.K.) as previously described (9) . Genotyping in the GoDARTS cohort was performed using custom genotyping arrays (including Immunochip, Cardio-Metabochip [Metabochip], and Human Exome array) from Illumina as previously described (17) . Genotyping in the DCS cohort was performed with Illumina's HumanCoreExome Array and imputed using IMPUTE2 (18) into the 1,000 Genomes March 2012 reference panel. All SNPs had an INFO (Information content metric in PLINK) .0.8.
T1D GRS calculation was not performed if genotyping results were missing for either of the two alleles with the greatest weighting (DR3/DR4-DQ8 or HLA_DRB1_15) or if more than two of any other SNPs were missing.
Statistical Analysis
We assessed the relationship between time to insulin treatment and each of GADA and T1D GRS using survival analysis. For this analysis, T1D GRS was categorized based on centiles of a population with type 1 diabetes (Wellcome Trust Case Control Consortium [16] ): ,5th centile (,0.234 [low]), 5th-50th centile ($0.234 and #0.280 [medium]), and .50th centile (.0.280 [high]) as previously reported (9, 19) . GADA was dichotomized into negative or positive based on the cutoff for positivity. Participants were then classified into six risk groups from these categories: 1) GADA negative, low T1D GRS, 2) GADA negative, medium T1D GRS, 3) GADA negative, high T1D GRS, 4) GADA positive, low T1D GRS, 5) GADA positive, medium T1D GRS, and 6) GADA positive, high T1D GRS.
Time to insulin data were censored at 5 years (or the latest available time point not on insulin, if earlier). Survival distributions for time to insulin, stratified by risk groups, were estimated using the Kaplan-Meier product limit estimator (20) . The proportional hazard assumption was checked visually and failed. Differences in time to insulin among risk groups were therefore compared using the Wilcoxon (Breslow) test. Positive predicted values were obtained from the product limit estimator, which makes allowances for censored observations.
To assess whether clinical characteristics were different across risk groups, we performed the Wilcoxon test for trend (21) on the continuous variables and Pearson x 2 test for categorical variables.
To assess whether GADA, T1D GRS (as a continuous covariate), age of diagnosis, and BMI (closest available to diagnosis, median 3 years diabetes duration) are independent predictors of rapid progression to insulin, we performed multivariate Cox proportional hazards regression analysis (22) . When T1D GRS was used as a continuous covariate, the proportional hazard assumption was satisfied. T1D GRS and GADA were added in as separate variables and as an interaction term. The log-linearity assumption was checked by examining Martingale-based residual plots and considered valid. Study of origin was included as a strata variable to control for effects of cohort differences.
As a 10 SNP T1D GRS combining the 10 alleles with the greatest weightings ordered by published odds ratios ( Supplementary Table 3 ) has also been proposed for clinical practice, we repeated survival analysis using T1D GRS defined by this 10 SNP score using the same centile cutoffs for categorization (9) . We also estimated survival distributions for risk groups based on imputed HLA-DR3/DR4 genotypes, individually and grouped by number of copies of at-risk alleles.
Median follow-up time was calculated using the reverse Kaplan-Meier method (23) . All analysis was performed in Stata/ SE 15.1 (StataCorp, College Station, TX).
RESULTS
We identified 8,608 participants with a clinical diagnosis of type 2 diabetes meeting all of our inclusion criteria. Table  1 shows the characteristics for these participants. A total of 79.9% (n = 6,879) had been followed for at least 5 years; median follow-up time, calculated as the median time to censoring (insulin treatment or latest follow-up), was 10.5 (95% CI 10.3, 10.6) years. A total of 7.8% (n = 533) of those participants with over 5 years' follow-up had progressed to insulin #5 years, and 3.3% (n = 280) of participants were GADA positive (measured at a median 6.1 years diabetes duration). The distribution of participants by low, medium, and high T1D GRS category was 53.2% (n = 4,580), 40.7% (n = 3,504), and 6.1% (n = 524), respectively. Characteristics of the participants stratified by cohort are shown in Supplementary Table 4 .
High T1D GRS Is Associated With Markedly Higher Rates of Rapid Insulin Requirement in Participants With
Positive GADA, but Is Not Associated in Those Who Are GADA Negative T1D GRS was strongly predictive of rapid insulin requirement in participants with positive GADA (Fig. 1) . In GADA-positive participants, those with higher T1D GRS progressed to insulin more quickly (P = 0.001); the probability of requiring insulin at 5 years postdiagnosis (positive predictive value) (95% CI) was: 47.9% (35.0%, 62.78%) (high T1D GRS) vs. 27.6% (20.5%, 36.5%) (medium T1D GRS) vs. 17.6% (11.2%, 27.2%) (low T1D GRS).
T1D GRS was not associated with rapid insulin requirement in GADA-negative participants. For the GADA-negative participants, the probability of requiring insulin at 5 years postdiagnosis was similar across all risk groups (P = 0.4): 7.4% (5.3%, 10.3%) (high T1D GRS) vs. 7.3% (6.5%, 8.3%) (medium T1D GRS) vs. 6.7% (5.9%, 7.5%) (low T1D GRS).
Differences in T1D GRS Were Associated With Higher HbA 1c and Lower BMI in GADA-Positive Participants but No Differences in Other Clinical Features
The characteristics of the GADA-positive and -negative participants split by T1D GRS category are shown in Table 2 . In GADA-positive participants, HbA 1c increased (P = 0.04) and BMI decreased (P = 0.01) with higher T1D GRS category. In GADA-negative participants, clinical characteristics were similar across all categories of T1D GRS. When comparing the characteristics of GADA-positive and -negative participants (Table 2) , GADA-positive participants had a higher T1D GRS (median 0.251 vs. 0.231; P , 0.001) and a lower BMI (median 28.73 vs. 30.48; P , 0.001) but similar age of diagnosis (median 59 vs. 60 years; P = 0.052).
T1D GRS and GADA Are Predictors of Rapid Insulin Requirement and Are Independent of Age and BMI Table 3 shows the Cox proportional hazards regression model for time to insulin (censored at 5 years) controlled for effects of cohort differences. As expected, the presence of GADA was a significant predictor of time to insulin (hazard ratio [HR] 3.43 [2.50, 4.71]; P , 0.001). T1D GRS was independently associated with time to insulin, but only in the presence of GADA (HR per 1-SD increase in T1D GRS 1.48 [1.15, 1.90]; P = 0.002). These associations were independent of age at diagnosis and BMI. The association between the 10 SNP T1D GRS and rapid insulin requirement was consistent with our findings using the full 30 SNP T1D GRS. The 10 SNP T1D GRS was associated with rapid insulin requirement in the GADA-positive risk groups (P , 0.001) but was not associated in the GADA-negative groups (P = 0.4) ( Supplementary Fig. 2 ). In the Cox proportional hazards regression model ( Supplementary Table 5 ), the 10 SNP T1D GRS was independently associated with future insulin treatment in GADApositive participants (HR per 1-SD increase in T1D GRS 1.34 [1.05, 1.71]; P = 0.02). Kaplan-Meier plots for HLA-DR3/DR4 genotype risk groups, individually and grouped by number of atrisk alleles, are shown in Supplementary  Figs. 3 and 4 .
CONCLUSIONS
In this large study of participants with a clinical diagnosis of type 2 diabetes, we have found that type 1 genetic susceptibility alters the clinical implications of a positive GADA when predicting rapid time to insulin. GADA-positive participants with high T1D GRS were more likely to require insulin within 5 years of diagnosis, with 48% progressing to insulin in this time in contrast to only 18% in participants with low T1D GRS. The T1D GRS was independent of and additive to participant's age of diagnosis and BMI. However, T1D GRS was not associated with rapid insulin requirement in participants who were GADA negative.
To our knowledge, this is the first study to assess the association between an integrated assessment of type 1 genetic risk and GADA in patients with type 2 diabetes or LADA. A key strength of this study is the use of large, predominantly population-based, cohorts of participants diagnosed with type 2 diabetes and, to date, is the largest cohort with measured GADA in a Western population. This means our results are likely to reflect true associations in patients seen in clinical practice. An additional key strength is the use of a single laboratory and assay for measuring GADA across cohorts, with a very robustly defined threshold for positive GADA based on a large, predominantly adult control population. We have demonstrated that our results are independent of and additive to participants' clinical features.
A limitation of our study is that time to insulin has been self-reported in the Exeter cohorts at a single visit, in contrast to other cohorts in which electronic health care records were available. Insulin commencement was also based on clinical decision making rather than a trial protocol. Both of these aspects may introduce imprecision but because both clinicians and participants were unaware of the results, systematic bias would be unlikely. An additional limitation of cross-sectional study design is that GADA was measured at a median 6.1 years diabetes duration, which could result in a lower prevalence than if measurement was undertaken at diagnosis. However, in adult populations, the difference is likely to be small, with GADA positivity being stable over the first 6 years in the UK Prospective Diabetes Study (UKPDS) participants (adult-onset type 2 diabetes) (24) and a modest reduction in prevalence (from 72 to 63%) observed after 8 years in adult-onset type 1 diabetes (25) . The results of this study can only be applied to white European populations, and we do not have measurement of other islet autoantibodies in this cohortdthe interaction between genetic risk and other islet autoantibodies would be an area of interest for future research (26) .
Our findings are consistent with previous research in a population of participants diagnosed with diabetes between 20 and 40 years of age, in whom the same T1D GRS was predictive of insulindependent diabetes (9) , and other work that has shown this risk score to be additive to islet autoantibodies in predicting future type 1 diabetes (27,28). It is also consistent with previous research showing patients defined as LADA who have HLA type associated with type 1 diabetes susceptibility have more rapid progression to insulin (8) , and with research showing a combination of positive islet cell autoantibodies and high-risk HLA is associated with low C-peptide in a cohort diagnosed as having type 2 diabetes in contrast to either of these features alone (29) . Although the relationship between integrated genetic risk of type 1 diabetes and progression of type 2 diabetes or LADA has not been previously assessed, it has previously been shown that a type 2 diabetes genetic risk score covering 61 established type 2 diabetes risk variants is not associated with time to insulin (17) and that a 69 SNP type 2 diabetes genetic risk score has very limited utility in discriminating patients with type 1 from type 2 diabetes (9) .
The prevalence of positive GADA in our cohorts was lower than in much of the previous literature, with previous multicenter studies reporting widely varying prevalence of positive GADA in populations with type 2 diabetes ranging from 4 to 14% (30, 31) . In addition to diabetes duration, differences in the prevalence of GADA positivity between our and other studies may be explained by our use of an assay with higher specificity than used in many other studies (30) (31) (32) (33) (34) , our lack of an upper age limit (with lower GADA prevalence seen at older ages [4, 34, 35] ), and our use of predominantly population cohorts not selected from secondary care in which treatment with insulin is more frequent. We have used a robustly defined high specificity (97.5%) threshold to define positive GADA in line with current clinical laboratory practice using a large control population. Detectable GADA are commonly found in healthy adult populations without diabetes, and therefore, a threshold based on a control population is recommended to robustly define GADA positivity (32) (33) (34) . An additional potential reason for low autoantibody prevalence is that we have excluded a small number of cohort participants who had GADA tested in clinical practice, which may have influenced treatment choice. However, only 47 participants were excluded, of whom only 13 were GADA positive, so the effect on overall prevalence is small.
Our findings have clear implications for clinical practice. The T1D GRS represents a novel clinical test that can be used to enhance the prognostic value of GADA testing. For predicting future insulin requirement in patients with apparent type 2 diabetes who are GADA positive, T1D GRS may be clinically useful and can be used as an additional test in the screening process. However, in patients with type 2 diabetes who are GADA negative, there is no benefit gained from genetic testing. This is unsurprising, as the prevalence of underlying autoimmunity in patients with a clinical phenotype of type 2 diabetes who are GADA negative is likely to be extremely low; therefore, most GADA-negative participants with high T1D GRS will have nonautoimmune diabetes. The use of this two-step testing approach may facilitate a precision medicine approach to patients with apparent type 2 diabetes; patients who are likely to progress rapidly are identified for targeted management, which may include increased monitoring, early therapy intensification, and/or interventions aimed at slowing progression (36, 37) . The costs of analyzing the T1D GRS are relatively modest and may fall further, as genetic testing is rapidly becoming less expensive (38) . Although the test cost could potentially be reduced further by using 10 SNPs or imputing HLA type alone, the majority of test costs are attributable to DNA extraction, sample handling, and test interpretation, with cost for genotyping additional SNPs as low as 10 cents per SNP. Savings would therefore be modest, and, although this study does not have sufficient statistical power to directly compare different risk scores in antibody-positive participants, this may come at a cost of reduced test accuracy. The use of a risk score approach has an additional advantage over using HLA alone, as it provides genetic information expressed as a simple-to-use continuous variable.
Although using the T1D GRS alone in those who are GADA positive may have clinical utility, approaches that go beyond single tests and thresholds to integrate the T1D GRS with other predictors of insulin requirement may be the optimal way to use this investigation. The T1D GRS provides a continuous measure of risk, and therefore, dichotomizing the result to use thresholds will lose predictive value. It is additive to other predictive features (for example, age of diagnosis, which is freely available). Although the negative predictive value of a low T1D GRS in participants with GADA is high (,5th centile 82%), positive predictive values are modest, with the majority of high T1D GRS participants not requiring insulin by 5 years. Therefore, approaches that combine different predictive features on a continuous basis, using prediction models (clinical calculators), may have the greatest utility in accurately predicting future insulin requirement in this group and are an important area for future research (39) . Additional areas for future research include the association between T1D GRS and progression in which multiple islet autoantibodies have been tested and assessment in a prospective setting in which islet autoantibodies have been measured at diabetes diagnosis.
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